PYPD Polypid

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025.

Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid’s presentation will be available on-demand beginning on Wednesday, February 12, 2025 at 11:20 AM Eastern Time  and for 365 days after via the conference platform or using the following .

The PolyPid management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with PolyPid at the conference should contact their Oppenheimer representative.

About PolyPid

 (Nasdaq: ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit  and follow us on  and .

Contacts:

PolyPid Ltd. 

Ori Warshavsky

COO – US

908-858-5995

Investors:

Brian Ritchie

LifeSci Advisors

212-915-2578



EN
30/01/2025

Underlying

PYPDPolypid

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid to Participate in The Citizens Life Sciences Conference PETACH TIKVA, Israel, April 22, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will participate in a fireside chat at The Citizens Life Sciences Conference taking place in New York, NY, from May 7-8, 2025. Citizens Life Sciences Conference Fireside ChatDate:Wednesday, May 7, 2025Time:10:30 AM ET   The PolyPid management team will participate in one-on-one investor meetings duri...

April 22, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIEL...

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections Last Patient Enrolled Following Positive Recommendation by DSMB to Conclude Enrollment of Phase 3 Trial at 800 Patients; Top-line Results Expected by End of Q2 2025 and, if Positive, Expected to be Followed by Submission of an NDA to the FDA Leveraging the Company’s Fast-Track and Breakthrough Therapy Designations PETACH TIKVA, Israel, March 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ) (“PolyPid” or the “Company”), a late-stage bio...

March 11, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid to Participate in the 37th Annual ROTH Conference PETACH TIKVA, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the 37th Annual ROTH Conference taking place in Dana Point, California, from March 17-18, 2025. PolyPid’s fireside chat will be available on-demand beginning on Monday, March 17, 2025, at 2:00 PM PT via the conference platform using the following . The PolyPid management team will par...

March 3, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-...

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients to Date; Enrollment Completion Expected in March 2025, with Top-Line Results Anticipated in Second Quarter of 2025 Company Completed Private Placement of Up to $41 Million; Proceeds and Exercise of Data-Triggered Warrants Expected to Extend Cash Runway Beyond Potential NDA Approval Conference Call Scheduled for Today at 8:30 AM ET PETACH TI...

February 12, 2025 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life ...

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company’s management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025. Oppenheimer 35th Annual Healthcare Life Sciences Conference PolyPid’s presentation will be available on-demand beginning on Wednesday, February ...

January 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch